Faeth Therapeutics, Inc.

Faeth Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing cancer therapies that target tumor metabolism and signaling pathways. Its lead program, PIKTOR, is an all-oral combination of serabelisib and sapanisertib designed to inhibit multiple nodes of the PI3K/AKT/mTOR pathway.

5.06

5.06

— Faeth Therapeutics, Inc.
%
Clinical-stage oncology therapeutics100% Investigational cancer drug candidates being advanced through clinical trials.

Faeth does not sell commercial products today; its direct counterparties are clinical investigators, trial sites,...

  • Clinical development partnersprimary

    CROs, investigators, and CMOs that execute trials and supply manufacturing for product candidates.

  • Oncology physicians and cancer centersprimary

    Future prescribers and treatment centers that would adopt approved therapies if clinical data support use.

  • Patients with advanced solid tumorsprimary

    Patients in indications such as endometrial and HR+/HER2- breast cancer targeted by the pipeline.

  • Third-party payorssecondary

    Payers that would determine reimbursement and access after regulatory approval.

Faeth is headquartered in the United States and conducts its development activities through a U.S...

  • •United States is the core operating and regulatory base
  • •FDA oversight is central to clinical and commercialization plans
  • •Future product sales could extend to overseas markets
  • •Supplier and manufacturing exposure can include China-based inputs
  • •Clinical trial activity is tied to oncology centers and partners

The company’s strategy is to advance PIKTOR through clinical trials and build evidence in specific oncology...

01
Advance PIKTOR clinical developmentshort-term

Clinical data are the main value driver for a clinical-stage biotech with no product revenue.

02
Secure commercialization pathwaymedium-term

Any approved product will require sales, marketing, and distribution capabilities or partners.

03
Broaden oncology pipelinelong-term

A broader pipeline can diversify scientific risk and improve long-term optionality.

Faeth faces the classic risks of a clinical-stage biotech: trial failure, regulatory delay, and uncertainty around...

high

Clinical development failure

Drug candidates may not show sufficient efficacy or safety in trials, which can end programs.

Scope
PIKTOR and other oncology candidates
Materiality
high
high

Regulatory approval risk

FDA or other regulators may require additional data, delay review, or reject applications.

Scope
All product candidates
Materiality
high
high

Commercialization execution risk

The company may not build internal sales and marketing capabilities or secure effective partners.

Scope
Future approved products
Materiality
high
medium

Supplier and manufacturing dependence

Clinical materials and specialty inputs are sourced through third parties with limited redundancy.

Scope
Reagents, specialty materials, CMOs
Materiality
high
medium

China supply-chain exposure

Some suppliers or sub-suppliers are based in China, increasing geopolitical and trade risk.

Scope
Raw materials and reagents
Materiality
medium
Acquired in-process research and development
Can materially distort period-to-period comparability
Research and development expense timing
Quarterly results can be volatile based on trial activity
Stock-based compensation
Affects operating loss and non-cash expense profile
Fair value measurement
Can materially affect balance sheet and earnings

Phathom Pharmaceuticals, Inc.

PHAT · Pharmaceutical Preparations

AMICUS THERAPEUTICS, INC.

Pharmaceutical Preparations

GALECTIN THERAPEUTICS INC

GALT · Pharmaceutical Preparations

VERTEX PHARMACEUTICALS INC / MA

VRTX · Pharmaceutical Preparations

FATE THERAPEUTICS INC

FATE · Biological Products, (No Diagnostic Substances)

Larimar Therapeutics, Inc.

LRMR · Pharmaceutical Preparations

: 2.7.2026